"Transfer factor is a highly concentrated immune messaging system, designed by nature to transfer critical immune programming from one individual to another." William J. Hennen, Ph.D. Biochemist
Independent Study Results
4Life Transfer Factor™ & Transfer Factor Plus™
"Unprecedented" Immune Boosting Ability
| .
4Life Transfer Factor™ and Transfer Factor Plus™ were tested for their ability to increase Natural Killer Cell (NK) activity by killing live cancer cells. The research used peripheral blood mononuclear cells (PBMC) isolated from human volunteers. Test results showed that 4Life Transfer Factor™ increased the NK cell activity 103% above immune response without supplementation, more than two times higher than the next highest product. The study also showed | . NK cell Activity 248% above normal immune response without supplementation, or about five times higher than any of the other previously tested products.
Natural Killer Cells are an important part of our body's defense against infection and sickness. They seek and destroy infected or malignant cells and cells infected by viruses (colds/flu's).
David Lisonbee, President of 4Life Research™, in response to this research said, "These recent findings support and substantiate the reports form thousands of distributors who use Transfer Factor™ and Transfer Factor Plus™. The study also supports many other clinical experiences and studies we are familiar with. We are very pleased with the study results—they come as no surprise to us" |
JEUNESSE Inc.
Institute of Longevity Medicine
PRELIMINARY REPOT (additional test results to follow)
Transfer factor testing
11-5-99
Background and rationale: 1) Cancer is the second leading cause of death in the US. The rate of nearly every type of cancer is on the rise. Despite billions of dollars in research, the mortality rate has remained nearly unchanged since the 1960's using conventional treatments such as radiation, surgery and chemotherapy. Thus, there is considerable interest in using immune modulation as an adjuvant for cancer therapy. Natural killer cells are particularly important in destroying cancer cells.
Purpose of study: 1) To determine the in vitro anti-cancer effects of Transfer Factor and Transfer Factor Plus using PBMC isolated from human volunteers and assaying the increased ability of the NK cell population to kill K562 erythroleukemic cells.
Methods: 1) PBMC killing of K 562 (erythroleukemic) cells
Results 1) Transfer Factor increased NK-cell killing by 100%
and Transfer Factor Plus by 250%
Conclusions: Transfer Factor and Transfer Factor Plus induced immune based lysis of K562 cells at a level unprecedented in the director's experience or in the known medical literature. Since NK cell function is so crucial in killing cancer cells, these products (4Life Transfer Factor™ & Transfer Factor Plus™) are ideal candidates for cancer adjuvant therapy. In addition, NK cells form a first line of defense against infections from viruses and certain other microorganisms. Killing assays against K562 cells have also been correlated with increased with increased activity against chronic and acute infections as well.
Transfer Factor and Cancer
Dr. See AbstractsThe study that Dr Darryl See carried out on the 20 cancer patients that we have talked about and listened to from the conference calls has been published . 16 out of the 20 late stage (stage IV) cancer patients were alive and in remission after the 6 month study (see below / click this link for the abstract of the publication).
We have subsequently heard from Dr Darryl that at 8 months and later an update from Dr Foo that at 12 months the 16 patients were still alive and in remission or getting better .
Dr Darryl See was very excited to use Transfer Factor Plus which he found to have "unprecedented" and very exciting immune boosting and modulating properties. The Transfer Factor plus had raised the NK cell to the extent that it was 500 % higher than the next highest product. In his conference call he said he chose to give Transfer Factor the "most severe test", and chose end stage cancer patients to further study Tranfer Factor plus. In the study he used some additional nutritional supplement to support the patients.
Immunol Invest 2002 May;31(2):137-53
Increased tumor necrosis factor alpha (TNF-alpha) and natural killer cell (NK) function using an integrative approach in late stage cancers.
See D, Mason S, Roshan R.
Center for Advanced Medicine, Encinitias, California 92024, USA.
Natural products may increase cytotoxic activity of Natural Killer Cells (NK) Tumor Necrosis Factor alpha (TNF-alpha) while decreasing DNA damage in patients with late-stage cancer. Pilot studies have suggested that a combination of Nutraceuticals can raise NK cell function and TNF-alpha alpha activity and result in improved clinical outcomes in patients with late stage cancer. The objective of the study is to determine if Nutraceuticals can significantly raise NK function and TNF levels in patients with late stage cancer. After informed consent was obtained, 20 patients with stage IV, end-stage cancer were evaluated (one bladder, five breast, two prostate, one neuroblastoma, two non-small cell lung, three colon, 1 mesothelioma, two lymphoma, one ovarian, one gastric, one osteosarcoma). Transfer Factor Plus (TFP+, 3 tablets 3 times per day), IMUPlus (non denatured milk whey protein, 40 gm/day); Intravenous (50 to 100 gm/day) and oral (1-2 gm/day) ascorbic acid; Agaricus Blazeii Murill teas (10 gm/day); Immune Modulator Mix (a combination of vitamin, minerals, antioxidants and immune-enhancing natural products); nitrogenated soy extract (high levels of genistein and dadzein) and Andrographis Paniculata (500 mg twice, daily) were used. Baseline NK function by standard 4 h 51Cr release assay and TNF alpha and receptor levels were measured by ELISA from resting and phytohemagglutinin (PHA) stimulated adherent and non-adherent Peripheral Blood Mononuclear Cell (PBMC). Total mercaptans and glutathione in plasma were taken and compared to levels measured 6 months later. Complete blood counts and chemistry panels were routinely monitored. As of a mean of 6 months, 16/2ts were still alive. The 16 survivors had significantly higher NK function than baseline (p < .01 for each) and TNF-alpha levels in all four cell populations studied (p < .01 for each). Total mercaptans (p < .01) and TNF-alpha receptor levels were significantly reduced (p < .01). It was also observed that hemoglobin, hematocrit and glutathione levels were significantly elevated. The only toxicity noted was occasional diarrhea and nausea. The quality of life improved for all survivors by SF-36 form evaluation. An aggressive combination of immunoactive Nutraceuticals was effective in significantly increasing NK function, other immune parameters and hemoglobin from PBMC or plasma in patients with late stage cancers. Nutraceutical combinations may be effective in late stage cancers. Clinical outcomes evaluations are ongoing.
Studies of the 20 Cancer Patients pls click the LINK below;
Director, Bioassay Laboratory
Institute of Longevity Medicine
No comments:
Post a Comment